Vacuolar H + -ATPase-dependent (V-ATPase-dependent) functions are critical for neural proteostasis and are involved in neurodegeneration and brain tumorigenesis. We identified a patient with fulminant neurodegeneration of the developing brain carrying a de novo splice site variant in ATP6AP2 encoding an accessory protein of the V-ATPase. Functional studies of induced pluripotent stem cell-derived (iPSC-derived) neurons from this patient revealed reduced spontaneous activity and severe deficiency in lysosomal acidification and protein degradation leading to neuronal cell death. These deficiencies could be rescued by expression of full-length ATP6AP2. Conditional deletion of Atp6ap2 in developing mouse brain impaired V-ATPase-dependent functions, causing impaired neural stem cell selfrenewal, premature neuronal differentiation, and apoptosis resulting in degeneration of nearly the entire cortex. In vitro studies revealed that ATP6AP2 deficiency decreases VATPase membrane assembly and increases endosomal-lysosomal fusion. We conclude that ATP6AP2 is a key mediator of V-ATPase-dependent signaling and protein degradation in the developing human central nervous system.
Introduction
The vacuolar H + -adenosine triphosphatases (V-ATPases) are proton pumps present on endomembranes of all cells and acidify intracellular compartments, which is critical for numerous cellular processes, such as protein trafficking, maturation, recycling, or degradation (1) . In addition, V-ATPases have also been involved in acidification-independent roles such as membrane fusion or secretion (2) .
In lysosomes, V-ATPases regulate the optimal acidic pH for diverse enzymes to degrade macromolecules delivered from endocytic and autophagic pathways. In addition, lysosomal V-ATPases function as docking platform and amino acid sensors to regulate the activity of the mechanistic target of rapamycin complex 1 (mTORC1), a master regulator of cell growth and autophagy (3) . Although disruptions of lysosomal V-ATPasemediated functions may impair protein homeostasis (proteostasis) in different tissues, they are frequently linked to neurodegenerative disorders (4) . ATP6AP2 (ATPase, H + transporting, lysosomal accessory protein 2) on Xp11.4 encodes a type I transmembrane protein mostly studied for its role as (pro)renin receptor in the renin-angiotensin system (RAS) involved in blood pressure regulation (5) . The ATP6AP2 protein is mainly composed of an extracellular Vacuolar H + -ATPase-dependent (V-ATPase-dependent) functions are critical for neural proteostasis and are involved in neurodegeneration and brain tumorigenesis. We identified a patient with fulminant neurodegeneration of the developing brain carrying a de novo splice site variant in ATP6AP2 encoding an accessory protein of the V-ATPase. Functional studies of induced pluripotent stem cell-derived (iPSC-derived) neurons from this patient revealed reduced spontaneous activity and severe deficiency in lysosomal acidification and protein degradation leading to neuronal cell death. These deficiencies could be rescued by expression of full-length ATP6AP2. Conditional deletion of Atp6ap2 in developing mouse brain impaired V-ATPase-dependent functions, causing impaired neural stem cell self-renewal, premature neuronal differentiation, and apoptosis resulting in degeneration of nearly the entire cortex. In vitro studies revealed that ATP6AP2 deficiency decreases V-ATPase membrane assembly and increases endosomal-lysosomal fusion. We conclude that ATP6AP2 is a key mediator of V-ATPase-dependent signaling and protein degradation in the developing human central nervous system. ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration jci.org ATP6AP2 is highly expressed in the CNS, and human genetic studies suggested its potential involvement in diverse neuropsychiatric disorders. For instance, 2 synonymous variants in ATP6AP2 have been found to cosegregate in families with X-linked intellectual disability (XLID) and epilepsy (c.321C>T, p.D107D) (12) and X-linked parkinsonism with spasticity (XPDS) (c.345C>T, p.S115S) (13) . Intriguingly, both variants associated with these diverse disorders increase skipping of exon 4 (ATP6AP2Δe4) that encodes part of the extracellular domain, resulting in ATP6AP2Δe4 in about 50% of ATP6AP2 transcripts. However, the causative role of ATP6AP2 has been questioned (14) , since a potential splicing variant (NM_005765.2; c.859-2A>C) resulting in a truncated pro-(pro)renin binding domain that can be secreted after cleavage by furin; a transmembrane domain; and a short cytoplasmic domain (6) . The transmembrane/cytoplasmic part is present in species without renin, and the extracellular domain is only conserved in vertebrates. This suggests divergent functions of the ATP6AP2 domains and that its role in the RAS was acquired during vertebrate evolution (7) . Accumulating evidence now indicates that ATP6AP2 has important functions apart from the RAS, as a V-ATPase accessory protein (8) (9) (10) .
Recent studies in yeast and flies suggest that ATP6AP2 contributes to the assembly of the V-ATPase proton pore in the endoplasmic reticulum (11) . unknown. First studies of neuron-specific Atp6ap2-knockout mice suggested its involvement in central angiotensin II formation and salt-induced hypertension (17) . However, the blood pressure in XLID patients carrying ATP6AP2 (c.321C>T, p.D107D) was normal (18) . Another study in mice carrying a conditional postnatal Atp6ap2 deletion in postmitotic neurons has identified autophagy deficits associated with impairments of synaptic plasticity, myelination, and memory functions (19) .
Here, we identified a new ATP6AP2 variant resulting in expression of more than 80% ATP6AP2Δe4 in a patient with XLID and fulminant early postnatal neurodegeneration. We assessed the underlying cellular and molecular mechanisms using patient-derived tein is present in the Exome Variant Server (14) , and ATP6AP2Δe4 transcripts are naturally occurring splice isoforms in the human brain (13) . Furthermore, 2 missense mutations in exon 3 have recently been shown to be responsible for a glycosylation disorder with liver disease, immunodeficiency, and cutis laxa, and patients show signs of psychomotor impairments (15) . In another family, 2 affected siblings suffering from either XLID or parkinsonism have been described carrying a putative splice site mutation in ATP6AP2 (c.168+6T>A), downstream of exon 2. However, the functional relevance of this putative variant to splicing and ATP6AP2 function remains to be studied (16) . To date, the role of ATP6AP2 in development and function of the mammalian CNS remains largely ) and of an age-matched normal subject. Patient axial T2-weighted MR brain images (A and B) and normal subject brain images (E and F) for comparison. Patient coronal T2-weighted MR image (C) and normal subject (G). Patient MR images (A-C) exhibit diffuse parenchymal volume loss of gray and white matter. This is observed in the white matter tracts that travel adjacent to the prominently enlarged lateral ventricles (white arrows), as well as the prominent sulci (white arrowheads) in the cerebral hemispheres and cerebellum. Supratentorial and infratentorial parenchymal volume loss involves the cerebral hemispheres and cerebellum symmetrically. Sagittal T1-weighted MR brain image (D) compared with normal subject (H) demonstrates significantly reduced white matter volume of the corpus callosum (curved white arrows). There is also significant white matter volume loss in the patient cerebellum (D) with increased cerebrospinal fluid (asterisk) in the prominent posterior fossa mega cisterna magna. (I) ATP6AP2 genomic locus and positions of variant c.321C>T (p.D107D). (J and K) Schematics of ATP6AP2 and ATP6AP2Δe4.
Results
Rapidly progressing cerebral atrophy in a patient carrying an ATP6AP2 splice site variant. We identified a de novo intronic ATP6AP2 variant in a boy with XLID and fulminant early postinduced pluripotent stem cells (iPSCs) and provide converging evidence from Atp6ap2-conditional-knockout mouse lines and knockdown experiments. Our results show that V-ATPase functions in the developing CNS are critically dependent on the dosage of ATP6AP2. Figure 3A) , suggesting severe deficits in neural cell generation and/or survival. Immunostaining showed a substantial reduction of the transcription factor Pax6 ( Figure 3C ), essential for RGC proliferation and self-renewal (23 Figure  1C) . Correspondingly, the early neuronal marker Tuj1 was ectopically expressed in proliferative zones of the developing cortex ( Figure 3C ). Subsequently, these prematurely differentiating neurons underwent apoptosis as indicated by activated caspase-3 immunolabeling (Figure 3C and Supplemental Figure 1D ).
The premature progenitor differentiation and subsequent fulminant death of newborn neurons resembled observations in mice carrying a conditional deletion of Pals1 (protein associated with Lin7), encoding an apical complex protein. Rescue experiments in Pals1 mutants suggested a role for mTOR kinase signaling in coupling apical complex dysfunction in progenitors and neuronal cell death (24) .
We studied the expression of proteins involved in RGC polarity in Atp6ap2 mutants. Immunolabeling revealed that Pals1, Par3, Prom1 (prominin, CD133), or Cdc42, and adherens junction proteins Cdh2 (N-cadherin) and Ctnnb1 (β-catenin), were largely absent in Atp6ap2 cKO ( Figure 3D , Supplemental Figure 1B , and Supplemental Figure 2 ). The failure to detect a broad range of apical proteins in Atp6ap2 cKOs suggested severe deficits in fundamental cellular processes such as protein trafficking, recycling, or degradation interfering with multiple signaling pathways. This is supported by studies in mice with conditional Atp6ap2 deletion in postnatal neurons (19) , cardiomyocytes (9), or podocytes (10, 25) showing impaired autophagy and increased cell death.
Lysosomes are terminal compartments of endocytosis and autophagy and are signaling hubs to coordinate cellular responses to changes in nutrient availability via mTOR signaling (26) . We studied the involvement of Atp6ap2 in lysosomal functions in the developing cortex. We first assessed the subcellular localization of Atp6ap2 in RGCs using super-resolution stimulated emission depletion (STED) imaging on E12 wild-type cortical slices. Atp6ap2 was largely undetectable at the plasma membrane and was mostly found in intracellular punctae (Supplemental Figure 3) , suggesting main vesicular functions. Double immunolabeling of Atp6ap2 with lysosomal-associated membrane protein 1 (Lamp1) or with the small GTPase Rab5 or Rab7 showed partial costaining indicating its presence, particularly in lysosomes and in early and late endosomes, respectively (Supplemental Figure 3) . Lysosome positioning has been shown to regulate autophagic flux and mTOR signaling. With nutrients available, lysosomes are preferentially located at the cell periphery close to its upstream signaling elements and recruit and activate mTORC1. During starvation, lysosomes cluster in the perinuclear area and mTORC1 signaling is inhibited (27) . Confocal imaging of Lamp1 in Atp6ap2 mutants revealed enlarged lysosomes clustered in the perinuclear region, whereas lysosomes in controls were mostly distributed more apically ( Figure 4A ). Consistent with the perinuclear positioning of lysosomes in mutants, immunolabeling revealed decreased mTOR phosphorylation similar to starvation conditions natal neurodegeneration (patient 1). The patient was diagnosed at the age of 2 weeks with seizures and mild facial dysmorphism, with a short forehead and bitemporal narrowing. At 1 month his occipito-frontal head circumference was at the mean, but it decreased to ≤1.5 standard deviations (SDs) at 6 months and ≤2 SDs at 3 years. He developed intractable seizures and generalized limb spasticity. Sequential MRI at 5 weeks, 9 months, and 28 months of age showed rapidly decreasing cortical gray and white matter volumes, a thin, poorly developing corpus callosum, and myelination deficits ( Figure 1A ). Candidate gene sequencing revealed a deletion of 2 conserved nucleotides in intron 3 in ATP6AP2 (c.301-11_301-10delTT) (Figure 1 , B and C), a variant not present in genome databases of normal genetic variation in human populations. Furthermore, Sanger sequencing of flanking exons and introns (3) (4) (5) and the putative promoter region of ATP6AP2 did not reveal additional abnormalities. Human Splicing Finder (20) analysis predicted that the deletion disrupts a branch point motif (CTCTTAA) at position c.301-14 expected to increase exon 4 skipping. Accordingly, reverse transcription PCR (RT-PCR) of patient fibroblasts showed 20% full-length ATP6AP2 (fl-ATP6AP2) and 80% ATP6AP2Δe4 transcripts ( Figure 1 , D and E).
In addition, we performed MRI on a patient from the previously reported family (patient 2, proband IV-18; ref. 18 ) diagnosed with seizures and moderate mental retardation carrying ATP6AP2 variant (c.321C>T, p.D107D; Figure 2I ) resulting in about 50% ATP6AP2Δe4 transcripts (12) . MRI at the age of 15 revealed an abnormally thin corpus callosum and diffuse volume loss of cortical gray and white matter, although to a substantially lesser degree than in patient 1 ( Figure 2 , A-H). These results suggested neurodevelopmental deficits and/or neurodegenerative processes that prominently affect cortical regions in these patients.
Atp6ap2 is required for cortical development. We therefore studied neural Atp6ap2 functions in cortical development. We first analyzed its cortical expression in embryonic day 12 (E12) mice. Atp6ap2 was detectable throughout the developing cortex with notable apical enrichment in radial glial cells (RGCs) along the ventricular surface ( Figure 3B ). Characteristically RGCs are polarized, displaying a specialized apical membrane domain separated from the basolateral domain by adherens junctions. Apical-basal polarity is crucial for the distribution of cell fate determinants during RGC mitosis to balance the generation of progenitors and neurons (21) . The subcellular distribution of Atp6ap2 therefore may suggest its involvement in RGC polarity and ultimately cell fate choice, consistent with recent data in retinal progenitors, suggesting that Atp6ap2 interacts with polarity complex protein Par3 (partitioning defective 3 homolog) and that Atp6ap2 knockout disrupts the development of retinal lamination (22) .
To assess Atp6ap2 functions in corticogenesis, we generated mutant mice carrying a conditional deletion (Atp6ap2 lox/y Emx1-Cre +/-). In mutant male offspring (Atp6ap2 mutant or conditional knockout [cKO]), protein expression was undetectable by E12 (Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/JCI79990DS1). Mice were born at the expected Mendelian ratio, although mutant males showed a postnatal growth delay and died around 4 weeks of age. They displayed a flattened forehead corresponding with a lack of nearly their entire ( Figure 4A and Supplemental Figure 4A ). Starvation or lysosomal stress has been shown to promote lysosomal biogenesis, autophagosome formation, and fusion of autophagosomes with lysosomes (3). In mutants but not in controls, we detected increased punctae positive for the autophagosomal membrane protein LC3B that partially overlapped Lamp1 ( Figure 4A and Supplemental Figure 4 ). Electron microscopy in cortical progenitors revealed large, electron-dense vacuolar structures ( Figure 4B ). These results indicate induction of autophagy and accumulation of autophagosomes but deficient protein degradation in autophagolysosomes in mutants. This is further supported by cathepsin D Western blots on embryonic cortical tissue. The activation of this protease requires proteolytic processing in lysosomes and is pH dependent. Our results indicate that cathepsin D processing is impaired in cKOs ( Figure 4C ).
Taken together these results suggest that Atp6ap2 is a key regulator of V-ATPase functions during corticogenesis. Atp6ap2 deficiency may lead to dysfunctions of several V-ATPase-dependent cellular processes such as vesicular acidification, protein degradation, and mTOR signaling.
Postnatal neuronal knockout of Atp6ap2 impairs protein degradation and causes memory deficits.
Such ATP6AP2-dependent V-ATPase dysfunctions may also lead to neurodegenerative processes at later developmental stages or in adulthood, as suggested by the association of ATP6AP2 variant c.345C>T with XPDS (13). Therefore we studied mice carrying an Atp6ap2 deletion in postmitotic neurons in the forebrain including hippocampus and cortex starting around 1 month of age (Atp6ap2 lox/y CamK2a-Cre +/-). Around 4 months of age, mutants developed pathological hind-limb clasping reflexes during tail suspension ( Figure  5A ) and hyperactivity in the open field ( Figure 5B ), potentially representing early signs of neurodegeneration (28, 29) . We furthermore assessed long-term memory function using a hippocampusdependent contextual fear-conditioning task (30) . We found that 4-month-old mutants were indistinguishable from control littermates whereas at 6 months they displayed significantly impaired long-term memory ( Figure 5C ), suggesting a progression of neural dysfunction reminiscent of other neurodegenerative disorders. To test whether behavioral abnormalities were correlated with mor- Figure 7B ). The survival of developing cortical neurons is critically dependent on early spontaneous activity (34) . We measured spontaneous intrinsic neuronal activity in developing iPSC-derived cortical neurons at 45 DIV using calcium imaging (35) . We found that the number of spontaneously active neurons as well as the frequency of their activity was significantly lower in patient than in control iPSC-derived cultures (Figure 8 ). Thus ATP6AP2 deficiency may impair early spontaneous activity, which in turn may contribute to the fulminant neurodegeneration observed in the patient (36) .
ATP6AP2Δe4 impairs V-ATPase activity and functions. In order to gain further insights into ATPase dysfunctions due to the lack of the exon 4-encoded ATP6AP2 domain, we studied HeLa cells using siRNA-mediated knockdown yielding approximately 75% reduction of protein levels (Supplemental Figure 9 , A and B). LysoSensor assays showed that ATP6AP2 knockdown increased median vesicular pH from 6.07 to 6.54 with a notable decrease of the more acidic vesicles (pH 3.5-4.5) likely representing lysosomes. Cotransfection with fl-ATP6AP2 but not with ATP6AP2Δe4 restored pH to control levels, confirming that the exon 4-encoded domain is necessary for vesicular acidification (Supplemental Figure 9C) , consistent with previous results (37) . Overexpression of ATP6AP2 in HeLa cells did not change vesicular pH (Supplemental Figure 9D) . Furthermore, ATPase activity in lysosomal fractions of HEK293T cells was significantly reduced following ATP6AP2 knockdown and could be restored by cotransfection with fl-ATP6AP2 but not with ATP6AP2Δe4 (Supplemental Figure 10) .
We next assessed whether this acidification deficit is associated with impaired degradation of endocytosed proteins. We analyzed ligand-induced degradation of epidermal growth factor receptor (EGFR) (38) using a HeLa cell line with stable ATP6AP2 knockdown and found that ATP6AP2 knockdown causes delayed decay of EGFR (Supplemental Figure 11) . Although decreased activity of lysosomal hydrolases due to impaired vesicular acidification may account for this delay, inhibition of V-ATPase activity may also impair endosomal-lysosomal fusion (39) . We used time-lapse confocal microscopy to study fusion events following ATP6AP2 knockdown. LysoTracker Red was used to label lysosomal compartments, whereas endosomes were identified via uptake of a pulse of Oregon green 488 dextran; the subsequent appearance of yellow dots indicated fusion events. Whereas control cultures displayed a characteristic combination of "kissing" and fusion events, ATP6AP2 knockdown surprisingly caused a rapid and significant increase in fusion events especially in large perinuclear clusters. Cotransfection with fl-ATP6AP2 but not with ATP6AP2Δe4 restored fusion events to control levels (Figure 9 , A and B, and Supplemental Videos 1-4). Several recent studies have suggested that the V0 sector of the V-ATPase acts in vesicular membrane fusion independently from its function as proton pump, although this is still debated (40) (41) (42) (43) (44) (45) (46) (47) (48) . In any case, both lower proton pump activity of V-ATPases and increased vesicular fusion could be related to decreased membrane content of assembled V0-V1 holoenzyme complex. We assessed a phological signs of lysosomal pathway dysfunction, we performed immunostaining on hippocampus in 6-month-old mutants. Similar to observations in the embryonic brain, Lamp1 staining revealed an increased accumulation of enlarged lysosomal compartments clustered in the perinuclear region ( Figure 5D ). We further examined autophagosomes by staining for LC3B and its interacting partner p62/SQSTM1 that targets ubiquitinated proteins to autophagosomes. We found increased perinuclear staining and a significantly higher number of LC3 + and p62/SQSTM1 + punctae ( Figure 5D and Supplemental Figure 5 ). While we did not detect fulminant neuronal degeneration as measured by an increased immunoreactivity of the apoptosis marker activated caspase-3 (data not shown), immunostaining for glial fibrillary acidic protein (Gfap) suggested an upregulation and hypertrophic astrocytic processes as signs of gliosis typically associated with neurodegenerative processes. This was further supported by a reduced number of hippocampal neurons in the CA1 region ( Figure 5E ). Moreover, electron microscopy studies revealed an accumulation of electron-dense material in the same region ( Figure 5F ). Collectively, these data demonstrate that mature as compared with developing neurons are less sensitive to Atp6ap2 deficiency and undergo a protracted neurodegenerative process.
Abnormal "in vitro corticogenesis" of patient iPSC-derived neurons. To study whether increased exon 4 skipping causes lysosomal dysfunction during human cortical development, we generated iPSCs from patient 1 (Supplemental Figure 6 ). To provide further proof of causality of ATP6AP2Δ4 for observed phenotypes, we generated an isogenic control line by stable re-expression of fulllength ATP6AP2 (fl-ATP6AP2) in the patient iPSCs (Supplemental Figure 6F ). When sequentially cultured in media containing different growth factors, iPSCs recapitulate key steps of in vivo corticogenesis (31) . Control iPSCs organized after 20 days in vitro (DIV) into characteristic sphere-like structures termed neural rosettes resembling the cortical neuroepithelium, with PAX6 + progenitors at the luminal surface and TUJ1 + neurons in the outer layer (32). Patient-derived neural rosettes, however, showed TUJ1 + cells interspersed in the PAX6 + progenitor zone, suggesting premature and/or ectopic differentiation ( Figure 6B ). Western blots of iPSCs and their derived neuronal progenitors showed an upregulation of LC3B and p62, indicating that altered autophagy activity is already present at the earliest developmental stages (Supplemental Figure 7) . We used the acidotropic dye LysoSensor Yellow/Blue dextran to quantify vesicular acidification across a broad (3.0-9.0) pH range (33) . LysoSensor measurements showed a significantly increased mean vesicular pH in patient iPSC-derived cortical neurons suggesting an impaired V-ATPase function ( Figure  6C ). Associated lysosomal dysfunction was further supported by impaired proteolytic processing of cathepsin D in patient-derived progenitors as assessed in Western blots (Supplemental Figure 8) . However, the observed phenotypes did not impair the proliferation potential of patient iPSC-derived progenitor cells as assessed by PAR3, CDH2, and CTNNB1 expression and phospho-histone 3 immunolabeling ( Figure 6A ).
Impaired proteostasis, activity, and survival of patient iPSCderived neurons. We further studied early developing neurons. Electron microscopy of these neurons showed excessive accumulation of large vacuoles containing diverse material resembling jci.org with ATP6AP2Δe4 restored the V1B2-V0a1 ratio to control levels ( Figure 9C ). Furthermore we were able to confirm these results in patient iPSC-derived neural progenitor cells (Supplemental Figure 12) . Taken together these in vitro studies indicate that the lack of the exon 4-encoded ATP6AP2 domain impairs several V-ATPase-mediated functions.
potential change in V0-V1 composition by measuring the membrane ratio of the V0a1 subunit that has been involved in neurodegeneration (49) and of the V1B2 subunit highly expressed in the human brain (50) . We found that ATP6AP2 knockdown causes a significantly lower ratio of membrane-assembled V1B2-V0a1 as compared with controls. Cotransfection with fl-ATP6AP2 but not show individual values and mean ± SEM; n = 15 per group. *P < 0.05, ***P < 0.001, 1-way ANOVA followed by Bonferroni's post test.
jci.org
rons naturally undergo a remarkable developmental transformation as they mature, from susceptibility to inhibition of cell death (55) . Thus newborn Atp6ap2-deficient neurons may engage apoptosis pathways normally restricted more to the developmental period. Indeed we found that Atp6ap2 deficiency caused a strong upregulation of activated caspase-3, a cell death pathway that has been shown to decay with increased brain maturation (55) . The rapid induction of cell death in knockout mice, however, prevented further studies in early developing neurons. The hypomorphic ATP6AP2 mutation in patient iPSCs allowed generation of early neurons. These cells faithfully recapitulated the V-ATPase deficits and showed reduced early spontaneous neuronal activity, a known contributor to increased cell death susceptibility (34) . Thus these iPSCs can be instrumental for further mechanistic studies on neural V-ATPase functions.
Exon 4 encodes a part of the N-terminal extracellular/intravesicular domain (Figure 2 , J and K), outside of the initially identified V-ATPase interaction domain (56) . Studies in transfected HEK293T cells, however, found that the extracellular and transmembrane domains of ATP6AP2 interact with the V-ATPase subunit V0C. Moreover, the interaction of the extracellular domain with Wnt receptors has been shown to be required for Wnt signaling (8) . Furthermore, expression of ATP6AP2Δe4 in Atp6ap2-knockout fibroblasts failed to restore vesicular acidification, LC3-II accumulation, and V-ATPase biogenesis (37) . However, it remained unclear whether impaired folding or membrane incorporation of these exogenous truncated protein fragments into the large V-ATPase complex may contribute to these negative outcomes (37) . Our studies on patient iPSC-derived neurons are consistent with the above results and provide evidence for the requirement of the exon 4-encoded domain in V-ATPase functions. This encouraged us to perform additional dynamic in vitro studies to explore whether the fulminant time course of neurodegeneration in the patient corresponds with deficiency of V-ATPase-associated functions of the exon 4-encoded domain. We found that ATP6AP2Δe4 is insufficient to rescue the appearance of perinuclear clusters of fused endolysosomes only 24 hours after ATP6AP2 knockdown ( Figure  8A ). This suggests a rapid contribution of the exon 4-encoded domain to V-ATPase functioning. Further studies are needed to precisely delineate the potential direct and indirect roles of this domain in the regulation of V-ATPase functions.
Mutations of V-ATPase subunits in model organisms are often associated with severe phenotypes and death (57), hampering more detailed functional studies. In addition, few human disorders due to mutations affecting V-ATPases have been described. They mainly affect subunits conferring tissue specificity or subcellular localization, resulting in specific deficits such as renal tubular acidosis, deafness, or osteopetrosis (1). We found that ATP6AP2 is a key accessory protein for V-ATPase functions in the CNS and is essential for stem cell self-renewal and neuronal survival. Furthermore, the exon 4-encoded domain is involved in modulating V-ATPase activity in the CNS but is not required for ATP6AP2 functions as (pro)renin receptor (12) . These findings may have implications beyond this rare XLID for more common disorders.
Collectively the patient data suggest that reduced V-ATPase activity due to ATP6AP2 deficiency may have an interesting safety
Discussion
Here we studied a patient with fulminant neurodegeneration carrying a rare ATP6AP2 splice site mutation. We found that patient iPSC-derived neural cells and targeted Atp6ap2 knockout in the mouse brain converge on common phenotypes. This provides evidence for the causality of observed ATP6AP2 splicing imbalances in this rare disorder and indicates that the complete loss-of-function mouse models have genetic validity to study the involved molecular and cellular mechanisms.
The 2 patients with XLID due to an ATP6AP2/ATP6AP2Δe4 splicing imbalance show a substantially different time course and severity of brain atrophy prominently of cortical gray and white matter. Another synonymous variant in ATP6AP2, c.345C>T (p.S115S), causing an ATP6AP2/ATP6AP2Δe4 transcript ratio of approximately 50:50, was reported in a family with XPDS and primarily affected the striatum (13, 51) . Members of this family displayed a diversity of symptoms, of their severity, and of age of onset (between 14 and 58 years) (51) . Immunohistological studies on brain material from one individual who died at age 86 showed the presence of pathological Tau deposits and accumulation of p62/SQSTM1, suggesting defects in protein degradation and autophagy. Although the reasons for the clinical heterogeneity associated with the different ATP6AP2 splice site variants are still unclear, it may involve a specific expression pattern of splicing factors depending on developmental stage and brain region or neural cell type (13) . The splicing imbalances clinically manifest as neurodegenerative process along a continuum of ages from early development to adulthood, corresponding with the available amount of fl-ATP6AP2. An ATP6AP2/ATP6AP2Δe4 transcript ratio of approximately 20:80 ultimately leads to fulminant neurodegeneration in early development, while, in contrast, a transcript ratio of approximately 50:50 may affect primarily the CNS over a period of several years with no clinical symptoms in other organ systems. This suggests that although ATP6AP2 is widely expressed, the CNS is exquisitely dosage sensitive.
The patient iPSC-derived "in vitro corticogenesis" experiments suggest that cell polarity and proliferation potential of cortical stem cells are largely preserved, which is supported by the normal head circumference of the patient around birth. However human ATP6AP2-deficient progenitors appear, at least partly, to differentiate prematurely into neurons, which is consistent with our findings in Atp6ap2-knockout mice. These data are also compatible with V-ATPase dysfunctions in cortical progenitors. Expression of a dominant-negative V-ATPase subunit in vivo reduces endogenous Notch signaling, depletes cortical stem cells, and induces neuronal differentiation (52) . In Atp6ap2-knockout mice, we observed the lack of multiple apical enriched proteins in cortical stem cells. Given the multitude of fundamental cellular processes depending on V-ATPase activity, our results suggest severe deficits in protein trafficking, sorting, and recycling rather than dysfunction of a single signaling pathway. For example, the reduced levels of Ctnnb1, a downstream effector of the canonical Wnt signaling pathway, would likely affect cortical stem cell self-renewal (53) .
Differences in vulnerability of early developing and mature neurons have been noted in a number of neurodegenerative disorders associated with impaired lysosomal degradation (54). Neu- margin, affecting the brain while being more tolerated in other tissues. The animal studies suggest that while Atp6ap2 knockout rapidly inhibits stem cell self-renewal, the more mature brain appears less sensitive. This is potentially relevant to the development of V-ATPase inhibitors for brain cancers, which rely heavily on pH regulation for growth and invasion (58) . Dysfunctions of protein degradation pathways are also a hallmark of common neurodegenerative disorders. Rare genomic variants of major effect size causally linked to common neurodegenerative diseases have pointed to dysfunctions at multiple stages in lysosomal degradation pathways (59) . Deficits in particular at late stages of autolysosomal proteolysis due to impaired lysosomal acidification and signaling have been suggested as a trigger for toxic protein accumulations (33) . Therefore the identification of V-ATPase-associated molecules regulating V-ATPase activity in the CNS may deliver attractive targets for drug development. . Data show individual values and mean ± SEM. **P < 0.01, ***P < 0.001, 1-way ANOVA followed by Bonferroni's post test. jci.org penicillin/streptomycin (all from Life Technologies), and 12.5 ng/ml recombinant human basic FGF (Miltenyi Biotec). Control iPSCs were obtained from reprogramming of human foreskin fibroblasts (Fibro-GRO Xeno-Free Human Foreskin Fibroblasts, Millipore) with a Stemgent mRNA Reprogramming kit (Miltenyi Biotec) according to the manufacturer's instructions. The iPSC colonies were further expanded in KOSR medium onto inactivated mouse embryonic fibroblasts. All the cultures were performed at 37°C in a 5% CO 2 atmosphere. The iPSC lines were characterized by FACS analysis for the expression of pluripotent stem cell surface markers. Briefly, 10 5 cells were stained with a combination of BD Horizon V450-conjugated mouse anti-(MOI6). Forty-eight hours later, transduced cells were passaged onto a freshly ES-qualified Matrigel-coated (BD Biosciences) 60-mm dish in FibroGRO-LS medium. The next day, medium was switched to Nutristem medium (Miltenyi Biotec) and changed every day until the emergence of reprogrammed colonies. iPSC colonies were identified under a stereomicroscope (Lynx, Vision Engineering) at day 25 after transduction and were manually picked and plated onto Mitomycin C-inactivated (Sigma-Aldrich) mouse embryonic fibroblasts in KOSR medium composed of DMEM/F12 culture medium, supplemented with 20% KnockOut Serum Replacement, 0.1 mmol/l nonessential amino acids, 1 mmol/l l-glutamine, 0.1 mmol/l 2-mercaptoethanol, The number of yellow vesicles resulting from the fusion of lysosomes labeled with LysoTracker (Red) and endosomes labeled with Oregon green 488. Data show individual values and mean ± SEM; n = 6-7 from 3 independent experiments. *P < 0.05, **P < 0.01, 1-way ANOVA followed by Bonferroni's post test. (C) Membrane-bound V1B2 subunit of the V1 sector and V0a1 subunit of the V0 sector of the V-ATPase of transfected HeLa cells were analyzed by Western blot (left). The band intensity was quantified (right) as a ratio of V1B2 to V0a1. Data show individual values and mean ± SEM; n = 5-7 from 3 independent experiments. **P < 0.01, ***P < 0.001; NS, P > 0.05; 1-way ANOVA followed by Bonferroni's post test. jci.org
Fibroblast cell culture. Explants of 3-mm dermal biopsies were minced and placed in a 60-mm tissue culture dish under a sterile coverslip held down by sterilized silicon grease. Fibroblast medium (DMEM supplemented with 10% FCS, GlutaMAX, and penicillin/ streptomycin [Invitrogen]) was added, and dishes were incubated at 37°C in a humidified 5% CO 2 atmosphere with media exchange every 5 days. Fibroblast outgrowths were harvested by trypsinization, expanded in a T25 flask in fibroblast medium, and allowed to reach approximately 90% confluence before freezing or splitting for reprogramming as described below. For reprogramming, fibroblasts were used within the first 3 passages from biopsy or within 1 passage after a thawing.
Electron microscopy. Cells were fixed with 4% PFA and 2.5% glutaraldehyde in 0.1 M phosphate buffer (1 hour) and postfixed in OsO 4 (40 minutes) at 4°C. Samples were dehydrated in an ascending series of ethanol, and embedded in epoxy resin. Semithin sections (0.5 μm) were stained with toluidine blue and viewed with a Provis Olympus microscope. Images were acquired with a Coolsnap CCD camera. Ultrathin sections (40 nm thick) were mounted in 200 meshes, cut, and double-stained with uranyl acetate and lead citrate before observation with a Philips (CM-100) electron microscope. Digital images were obtained with a CCD camera (Gatan Orius). Morphometric analysis was performed with the software Digital Micrograph on 2 different experiments of each genotype. For lysosomal diameter, lysosomes were identified by their morphology as described previously (63) and their diameter measured in 10 neurons per genotype.
Animals. Mouse strains were on a C57BL/6 genetic background and have been described earlier: Atp6ap2 flox (10), Emx1-Cre (64), and CamK2a-Cre (65, 66) . All procedures were designed to minimize animal suffering and were carried out in accordance with European Economic Community guidelines (2010/63/UE) for the care and use of experimental animals and French National Committee guidelines (87/848) for the use of laboratory animals.
Behavior tests. Open field test and contextual fear conditioning were performed as described previously (67) . The open field test was conducted in a brightly illuminated square arena. Mice were placed in the center of the arena and allowed to explore the area for 30 minutes. Behavior was tracked using a ceiling-mounted camera (Panasonic WV BP332). For contextual fear conditioning, mice were placed in a conditioning chamber and allowed to habituate for 3 minutes, followed by 3 consecutive foot shocks (1.0 mA, 50 Hz, 1 second) separated by 1 minute. Animals remained in the chamber for 1 minute after the delivery of the last foot shock. Testing occurred 24 hours after in the same chamber, and freezing was scored for a total of 5 minutes. Sessions were recorded and freezing was manually scored blinded for genotype. Freezing was defined as complete absence of movement, except for respiration. Data were expressed as percentage of time freezing.
Immunohistochemistry. Sections of 40 μm (P15, 6 months) and 60 μm (E12, E13, E14) were prepared using a VT1000S vibratome (Leica Biosystems) and maintained at -20°C in cryoprotectant tissue collecting buffer (30% ethylene glycol, 30% glycerol in 0.024 M phosphate buffer). For frozen sections, brains were cryostat-sectioned into 5-to 10-μm slices (Leica CM1800, Leica Biosystems). Nonspecific binding was blocked by pretreatment with 5% normal goat serum in PBS containing 0.2% gelatin. The sections were incubated in primary antibodies overnight at 4°C in PBS 0.2% gelatin or 0.4% saponin. The list of antibodies is provided in Supplemental Table 1 . BrdU and Ki67 staining human SSEA4 (Clone MC813-70, BD Biosciences), FITC-conjugated mouse anti-human HESCA1 (clone 051007-4A5, Millipore), phosphatidylethanolamine-conjugated (PE-conjugated) rat anti-mouse SSEA3 (clone MC631, BD Biosciences), and Alexa Fluor 647-conjugated mouse anti-human TRA-1-60 (clone TRA-1-60, BD Biosciences) according to the manufacturer's recommendations. Cells were analyzed on a MACSQuant flow cytometer (Miltenyi Biotec) using MACSQuantify software. The genomic integrity was assessed by karyotyping according to standard procedures. Following reprogramming, fl-ATP6AP2 and ATP6AP2Δe4 transcripts were present. Pluripotency of the iPSC line was assessed by teratoma formation assays. Six-week-old NSG mice were subjected to intramuscular injection of 2 × 10 6 to 3 × 10 6 iPSCs. After 8 weeks, teratomas were dissected and fixed in 4% paraformaldehyde (PFA) and samples embedded in paraffin and stained with H&E. For re-expression of fl-ATP6AP2, the patient iPSC line was transduced with a pHAGE lentiviral vector (60) carrying mCherry cDNA and the cDNA of the fl-ATP6AP2. The patient control line was generated with the same vector without the ATP6AP2 cDNA. The mCherry-expressing cells were isolated by FACS.
Neuronal differentiation of iPSCs. Differentiation of iPSCs into cortical neurons was performed as described previously (61) . Briefly, iPSC colonies were detached by treatment with type IV collagenase and kept in suspension in low-attachment plates (Corning) as embryoid bodies (EBs) during 5 days in iPSC culture media without . Western blots for p62 and LC3B were performed according to guidelines for autophagy assays (62) . Calcium imaging. The iPSC-derived neurons at 45 DIV were bulk-loaded with 5 μM of Fluo4-AM (Life Technologies) in culture medium for 15 minutes at 37°C. Then the culture medium was removed and replaced by an imaging medium: MEM, 4 mM sodium bicarbonate, 20 mM HEPES, 2 mM GlutaMAX, 33 mM d-glucose, B27, and N-2 serum. During imaging, iPSCs were perfused at a rate of 1 ml/min with imaging medium at 32°C. Images were obtained with an upright microscope DM6000CFS (Leica Microsystems) equipped with a ×25 0.95 numerical aperture water-immersion objective and a CCD camera (DFC 360 FX, Leica Microsystems). Illumination was by a short-arc HXP lamp (Osram); exposure times were 0.1-0.2 seconds. Excitation and dichroic filters were D480/40 nm and 505 nm, respectively. Signals were acquired behind an emission filter (527/30 nm). Recorded fluorescence movies (1 image per second during 5 minutes) were first corrected for movement artifacts using the StackReg plug-in for ImageJ (NIH). The calcium signal for each detected cell was extracted from stable portions of movies. In these traces, the large deflections indicate calcium events that correspond to the increase of neuronal activity. The onset of each deflection was marked and used for building Rasterplots (MATLAB). jci.org containing 125 mg/ml Hygromycin B (Invitrogen). Cells were starved with 0.1% FCS/DMEM (without antibiotics) for 20 hours and then preincubated with 10 mg/ml cycloheximide for 30 minutes and stimulated with 100 ng/ml recombinant human EGF (236-EG-200, R&D Systems) for 0, 30, 60, 120, 180, and 240 minutes, in triplicate. Cells were then washed with ice-cold PBS, lysed with lysis buffer (20 mM HEPES-KOH pH 7.4, 100 mM KCl, 0.5 mM EDTA, 10 mM NaF, 1% Triton X-100, 1 mM Na 3 VO 4 , 10 mM Na 4 P 2 O 7 , 0.1 mM Na 2 MoO 4 , β-glycerolphosphate, protease inhibitor cocktail [Complete, Roche Diagnostics]), and scraped. Cell lysates were analyzed by 7.5% SDS-PAGE and Western blotting with anti-EGFR (sc-03, Santa Cruz Biotechnology).
Cloning and expression. Expression vectors for either human fl-AT-P6AP2 cDNA or ATP6AP2Δe4 were generated from the patient with ATP6AP2 variant c.321C>T (p.D107D) (OMIM 300423) (72) and ligated into the KpnI/EcoRI site in pcDNA3.1(+) vector (Invitrogen) (Supplemental Table 2 ).
Vesicle fusion and live cell imaging. Endosome-lysosome fusion assays were adapted from Bright et al. (73) . Briefly, HeLa cells were seeded in 8-well Labtek II chambers and transfected with siRNA with or without rescue construct. Then cells were loaded with 50 nM LysoTracker Red (Life Technologies) for 4 hours followed by incubation in conjugate-free medium for 20 hours. Cells were then loaded with dextran Oregon green 488 (10,000 MW, anionic, fixable; Life Technologies) for 10 minutes followed by a 5-minute chase in conjugate-free CO 2 -independent medium (Invitrogen). Cells were washed 3 times with PBS and transferred to the heated stage, and spinning-disk images were acquired using a ×63/0.15 NA objective on a Nikon Eclipse Ti microscope, equipped with an Evolve 512/EM-CCD camera (Photometrics) and a CSUX1-A1 (Yokogawa) confocal scanner. Fluorescence was excited with a 491-nm laser and detected with a 525/39 nm filter for Oregon green 488. A 561-nm laser and 605/64 nm filter were used for LysoTracker Red. MetaMorph software (Molecular Devices) was used to collect the data and ImageJ to assemble the movies.
Membrane fractionation and Western blotting. To prepare membrane fractions, HeLa cells were homogenized with a Teflon potter in sucrose buffer, and the postnuclear supernatant was fractionated into cytosolic and membrane fractions by ultracentrifugation (60 minutes, 100,000 g) as described previously (74) . Alternatively, cell lysate was obtained by treatment of cells with lysis buffer (Cell Signaling) containing protease and phosphatase inhibitors. Total protein was separated on 10% or 16% SDS-PAGE and transferred to PVDF membranes (Millipore). The membranes were blocked with 5% nonfat dry milk or 5% BSA in 20 mM Tris-HCl pH 7.4, 150 mM NaCl with Triton X-100 for 30 minutes at room temperature and incubated overnight with primary antibodies at 4°C. Membranes were incubated with alkaline phosphatase-conjugated secondary antibodies (1:5000; Jackson ImmunoResearch) for 1 hour at room temperature. AttoPhos AP Fluorescent Substrate System (Promega) was used for detection, and quantification of bands was performed using ImageJ software. The primary antibodies used are listed in Supplemental Table 1 .
Statistics. R (version 2.14.0) (http://www.R-project.org) and GraphPad Prism software (version 8.0.1) were used for statistical analyses. A P value less than 0.05 was considered significant. Mann-Whitney U test, Student's t test (unpaired, 2-tailed), Kruskal-Wallis test, 1-way ANOVA, or 2-way repeated-measures ANOVA was performed for statistical analysis based on group numbers and data distributions. Bonferroni's correction for parametric analywas performed as described previously (53) . Alexa Fluor 488 or Alexa Fluor 555 fluorescent secondary antibodies (Invitrogen) were used for Leica laser-scanning 2-photon microscopy (Leica TCS SP5, Leica Biosystems), and secondary antibodies (Jackson ImmunoResearch) were conjugated to Atto 565 (ATTO-TEC) and DY 485 (Dyomics) and used for 2-color STED microscopy on a custom-built setup (68) .
Cell culture and transfection. HeLa (CCL-2) and HEK293T (CRL-3216) cells were obtained from the American Type Culture Collection and cultured in DMEM (Invitrogen) containing 10% FCS. Constructs, scramble, and siRNAs targeting the 3′-UTR (Dharmacon) were transfected into HeLa cells using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions.
Vesicular pH measurement, fluorescent microscopy, and image processing. Vesicular pH was determined as described previously (69) . Briefly, HeLa cells were seeded in 8-well Labtek II chambers (Thermo Fisher Scientific) and transfected with siRNA with or without rescue constructs. Twenty-four hours later, cells were incubated in 1 mg/ml LysoSensor Yellow/Blue dextran (Invitrogen) for 1 hour, with or without 100 nM bafilomycin. Cells were then washed twice in PBS. For each experiment, a pH standard curve was obtained by treatment of the cells with clamp buffers at pH 3.5-7.5. Cells were equilibrated in clamp buffer pH 3.5-7.5 (5 mM NaCl, 115 mM KCl, 1.2 mM MgSO 4 , 25 mM 2-morpholinoethanesulfonic acid [MES], pH 3.5-7.5) followed by washing in clamp buffer supplemented with 25 μM monensin and 10 μM nigericin (Sigma-Aldrich) for 20 minutes before imaging. All equilibration steps were performed in a 37°C, 5% CO 2 incubator. Imaging was performed on a heated stage (37°C). Cells were excited with attenuated UV light (357-373 nm) and observed in blue (W1; 417-483 nm) and yellow (W2; 490-530 nm) regions of the spectra. Images were collected on a Leica DM IRBE, using a ×63/1.25 NA objective over a period of 5 minutes. Sixteen-bit images were processed to subtract background fluorescence, and then ratio (W1/W2) images were generated using the image calculator function in ImageJ. Regions of interest corresponding to vesicles were generated using W2 and applied to ratio images to determine the W1/W2 ratio value of the vesicles for each pH clamp buffer. A standard curve was generated in GraphPad Prism to assign a predicted pH for W1/W2 values.
V-ATPase-dependent acidification of lysosomes. V-ATPase activity on lysosomes was investigated as described previously (70) . Briefly, HEK293T cells were plated into 10-cm plates coated with poly-d-lysine (Millipore) and transfected with siRNA and rescue constructs. The next day, the medium was replaced to 10% FCS/DMEM containing 2.0 mg/ml FITC-dextran (Sigma-Aldrich), and cells were incubated overnight. After starvation for 6 hours in serum-free DMEM, cells were scraped into fraction buffer and lysed by passage of the cell suspension through a 27-gauge needle 8 times. After removal of intact cells and nuclei by centrifugation at 2000 g for 10 minutes, the supernatants were centrifuged at 16,100 g for 15 minutes. Then the pellets, including FITC-dextran-containing lysosomes, were resuspended in 100 μl fraction buffer, and concanamycin A-sensitive V-ATPase proton pumping was assessed by a spectrophotometer (Varioskan LUX Multimode Microplate Reader, Thermo Fisher Scientific).
EGFR degradation. Epidermal growth factor receptor (EGFR) degradation was studied as described previously (71) 
